Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients

Marc Klapholz, Sri Ram Pentakota, Juan-Pablo Zertuche, Marshall McKenna, Willy Roque, Mark Forsberg, Johnathan Packer, Devika S Lal, Lisa Dever, Marc Klapholz, Sri Ram Pentakota, Juan-Pablo Zertuche, Marshall McKenna, Willy Roque, Mark Forsberg, Johnathan Packer, Devika S Lal, Lisa Dever

Abstract

Background: The utility of convalescent coronavirus disease 2019 (COVID-19) plasma (CCP) in the current pandemic is not well defined. We sought to evaluate the safety and efficacy of CCP in severely or life threateningly ill COVID-19 patients when matched with a contemporaneous cohort.

Methods: Patients with severe or life-threatening COVID-19 were treated with CCP according to Food and Drug Administration criteria, prioritization by an interdisciplinary team, and based on CCP availability. Individual-level matched controls (1:1) were identified from patients admitted during the prior month when no CCP was available. The safety outcome was freedom from adverse transfusion reaction, and the efficacy outcome was a composite of death or worsening O2 support. Demographic, clinical, and laboratory data were analyzed by univariate and multivariable regression analyses accounting for matched design.

Results: Study patients (n = 94, 47 matched pairs) were 62% male with a mean age of 58, and 98% (90/94) were minorities (53% Hispanic, 45% Black, non-Hispanic) in our inner-city population. Seven-day composite and mortality outcomes suggested a nonsignificant benefit in CCP-treated patients (adjusted hazard ratio [aHR], 0.70; 95% CI, 0.23-2.12; P = .52; aHR, 0.23; 95% CI, 0.04-1.51; P = .13, respectively). Stratification by pretransfusion mechanical ventilation status showed no differences between groups. No serious transfusion reactions occurred.

Conclusions: In this short-term matched cohort study, transfusion with CCP was safe and showed a nonsignificant association with study outcomes. Randomized and larger trials to identify appropriate timing and dosing of CCP in COVID-19 are warranted.

Trial registration: ClinicalTrials.gov Identifier: NCT04420988.

Keywords: COVID-19; convalescent plasma; hospitalized; matched cohort study; mortality.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

References

    1. JHU. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) Available at: . Accessed 15 July 2020.
    1. WHO. Coronavirus disease (COVID-19) pandemic, numbers at a glance Available at: . Accessed 15 July 2020.
    1. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382:2327–36.
    1. Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the treatment of Covid-19 - preliminary report. Reply. N Engl J Med 2020; 383:994.
    1. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130:1545–8.
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20:398–400.
    1. Duan K, Liu B, Li C, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv 2020.03.16.20036145 [Preprint]. 23 March 2020. Available at: . Accessed 23 March 2020.
    1. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020; 324:460–70.
    1. NIH. Available at: . Accessed 15 July 2020.
    1. Rubin R Testing an old therapy against a new disease: convalescent plasma for COVID-19. JAMA. 2020; 323::2114–7.
    1. CBER. Investigational COVID-19 convalescent plasma - emergency INDs Available at: . Accessed 24 March 2020.
    1. Austin PC Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28:3083–107.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Publishers; 1988.
    1. Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 2020; 130:4791–7.
    1. Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020; 7:CD013600.
    1. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples [published online ahead of print May 22, 2020]. Clin Infect Dis. 2020; doi:10.1093/cid/ciaa638.
    1. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2020; doi:10.1056/NEJMoa2023184
    1. Wilder JM The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States [published online ahead of print July 10, 2020]. Clin Infect Dis 2020; doi:10.1093/cid/ciaa959
    1. Roberts DJ, Miflin G, Estcourt L. Convalescent plasma for COVID-19: back to the future. Transfus Med 2020; 30:174–6.
    1. Restivo JSA, Karafin MS. Plasma products. In: Shaz BH, Hillyer CD, Reyes Gil M. Transfusion Medicine and Hemostasis. 3rd ed. Cambridge, MA: Elsevier; 2019:205–12.
    1. Dzik S COVID-19 convalescent plasma: now is the time for better science. Transfus Med Rev. 2020; 34:141–4.
    1. Smatti MK, Al Thani AA, Yassine HM. Viral-induced enhanced disease illness. Front Microbiol 2018; 9:2991.
    1. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. medRxiv 2020.03.11.20031096 [Preprint]. 27 March 2020. Available at: 10.1101/2020.03.11.20031096. Accessed 23 March 2020.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe